Annual report [Section 13 and 15(d), not S-K Item 405]

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.25.1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
12 Months Ended
Dec. 31, 2024
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

    

Year Ended December 31, 

($ in thousands)

    

2024

    

2023

Qbrexza®

$

25,114

$

25,410

Accutane®

19,407

20,168

Amzeeq®

5,009

6,201

Zilxi®

 

1,643

 

1,962

Other / legacy

3,961

5,921

Total product revenues

$

55,134

$

59,662

Schedule of other revenue

    

Year Ended December 31,

($in thousands)

2024

    

2023

Milestone payment from Cutia

$

1,000

$

Non-refundable upfront payment from Maruho

 

19,000

Royalties on sales of Rapifort® Wipes 2.5%

519

Total other revenue

$

1,000

$

19,519